Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthracycline (doxorubicin) after radiotherapy in pediatric and young adult glioblastoma
2024-519135-41-00Phase 2Authorised
- Sponsor
- Meyer Children's Hospital IRCCS
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in glioblastoma (GBM), giant cell glioblastoma (GC-GBM), Gliosarcoma (GS) and 3 more, sponsored by Meyer Children's Hospital IRCCS. Primary endpoint: Primary safety endpoint. Planned start Jan 2025; status: authorised.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)giant cell glioblastoma (GC-GBM)Gliosarcoma (GS)epithelioid glioblastoma (eGBM)diffuse astrocytoma
Beyond the preview
Go deeper on 2024-519135-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519135-41-00.